Skip to content
Screener

Retained Earnings at other companies

Eli Lilly logo
Eli LillyLLY
$31.89B+83.5%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$37.62B+11.7%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
-$3.81B-4.3%
AbbVie logo
AbbVieABBV
-$17.87B-87.6%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-$825.44M-3.4%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
-$504.51M-24.8%

Other financials

Income statement

See full
Operating income-$82.8M-31.2%
Net income-$74.1M-33.9%
EPS (diluted)-$1.06-11.6%

Balance sheet

See full
Cash & equivalents$451.8M+323%
Total debt$8.0M-31.9%
Total assets$1.3B+81.1%

Cash flow

See full
Operating cash flow-$55.6M-14.6%
CapEx$62.0K
Free cash flow-$62.8M+7.3%

Valuation

See full
Market cap$10.17B+380%
Enterprise value$9.73B+385%

Returns & leverage

See full
Current ratio32.6×+16.8×

Where this comes from

Reported directly by Apogee Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.

The source filing: Apogee Therapeutics, Inc.’s 10-Q, filed May 11, 2026.

Filed
May 11, 2026, 7:20 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-215698
Line itemMARCH 31,2026DECEMBER 31,2025
Commitments and contingencies (Note 9)
Stockholders' equity:
Common Stock; $0.00001 par value, 400,000,000 authorized, 75,323,726 issued and 74,882,396 outstanding as of March 31, 2026; 400,000,000 authorized, 69,038,943 issued and 68,401,349 outstanding as of December 31, 202511
Additional paid-in capital1,892,4111,464,561
Accumulated other comprehensive income (loss)(749)1,080
Accumulated deficit(635,870)(561,759)
Total stockholders’ equity1,255,793903,883
Total liabilities and stockholders’ equity$1,293,654$937,134

Item 6. [Exhibits](#item_6_exhibits) [71](#item_6_exhibits)

FAQ

What is Apogee Therapeutics, Inc.'s retained earnings?
Apogee Therapeutics, Inc. (APGE) reported retained earnings of -$635.87M in Q1 2026.
How has Apogee Therapeutics, Inc.'s retained earnings changed year-over-year?
Apogee Therapeutics, Inc.'s retained earnings decreased by 76.0% year-over-year, from -$361.26M to -$635.87M.
What is the long-term trend for Apogee Therapeutics, Inc.'s retained earnings?
Over 3 years (2022 to 2025), Apogee Therapeutics, Inc.'s retained earnings has grown at a 141.7% compound annual growth rate (CAGR), from -$39.79M to -$561.76M.
What does retained earnings mean?
Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.

Ask your AI about Apogee Therapeutics, Inc.'s retained earnings.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude